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CONCLUSIONS: GA was found to reduce relapses and clinical progression com-
pared with placebo, and clinical progression in comparison with interferons. Seri-
ous adverse events were comparable with interferons. Qualitative and quantitative
methods demonstrated that the benefits of GA outweigh the risks but the results
differ substantially depending on the quantitative risk-benefit model used.
PND4
A META-ANALYSIS OF THE DURATION OF CLINICAL EFFECT OF
ONABOTULINUMTOXINA IN CERVICAL DYSTONIA
Marsh W1, Monroe D2, Gallagher C3
1Shenandoah University, Winchester, VA, USA, 2Allergan, Austin, TX, USA, 3Allergan Inc,
Irvine, CA, USA
OBJECTIVES: Cervical dystonia is a disabling, painful condition involving involun-
tary movement and posturing of the head and neck. Botulinum toxin injections are
the standard of care in the symptomatic management of this condition, but need to
be re-administered regularly to maintain a stable improvement. The duration of
clinical effect and thus, frequency of need for reinjection may be dependent on the
product used and can impact annualized drug and health care utilization costs.
METHODS: A literature search was undertaken to identify prospective or retro-
spective studies reporting duration of effect of onabotulinumtoxinA (BOTOX®). A
formal meta-analysis was conducted using Comprehensive Meta-Analysis Version
2. Both a fixed effects and random effects model were performed. The quality of
each identified journal article was evaluated using the Cho & Bero Quality scoring
instrument by two separate investigators. Differences in scores were resolved
through conference. Subgroup analyses were performed on several moderating
variables including study quality and dose of onabotulinumtoxinA. RESULTS: Of
the identified potential journal articles, 13 studies met the inclusion criteria and
were used for the meta-analysis. The duration of effect of onabotulinumtoxinA in
cervical dystonia was found to be 13.7 weeks (95% CI 13.4 – 13.9 weeks) for the fixed
effects model and 13.5 weeks (95% CI 12.7 – 14.3 weeks) for the random effects
model. A meta-regression found that the higher the quality score, the shorter the
duration of effect. Another meta-regression found that doses of onabotulinum-
toxinA greater than 200U generally resulted in a longer duration of effect than
doses below 200U. CONCLUSIONS: Based on the published literature, the duration
of effect of onabotulinumtoxinA was 13-14 weeks. This suggests that, in general,
patients with cervical dystonia treated with onabotulinumtoxinA should require
approximately 4 treatments per year. A dose-effect for duration was also identified.
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OBJECTIVES: To assess the relative efficacy and safety of high (HD) and low dose
(LD) beta interferons (IFN-1a and FN-1b) and glatiramer treatments in relapsing-
remitting multiple sclerosis. METHODS: Systematic review of literature. A bibliog-
raphy search was carried out to identify primary studies on MEDLINE and EMBASE
until February 2011. Other databases consulted were: Cochrane library, Centre for
Reviews and Dissemination, ECRI, ISI Web of Knowledge e INHATA. Inclusion cri-
teria: 1) head to head randomized clinical trials; 2) patients with relapsing-remit-
ting multiple sclerosis; and 3) Outcomes: relapse rate, proportion of relapse-free
patients, time to first relapse, expanded disability status scale, magnetic resonance
imaging outcomes and adverse effects. A quality assessment was carried out to
estimate the internal validity of the selected studies and the quality of their evi-
dence. Indirect comparison were analysed when head to head studies weren’t
available. RESULTS: Eight studies were included in this report, 5 head to head
studies between HD and LD IFN and 3 studies which compared the HD beta inter-
ferons with glatiramer. No studies were found which compared LD beta interferon
and glatiramer. The included studies had moderate internal validity. Direct com-
parison between the three beta interferons LD 1-a, HD1-a and HD1-b showed that
all of them were effective and HD IFN were better than LD IFN. There was weak
indirect and direct evidence for similar efficacy between the HD IFN. The compar-
ison HD interferons and glatiramer did not show significant differences in their
relapse rate and MRI measures. CONCLUSIONS: 1) HD interferons showed greater
efficacy at short term in reducing relapses than low-dose interferon. Currently, the
estimation of the relative efficacy of two high-dose interferons is not possible but
there is weak evidence in favor of similar efficacy, and 2) HD interferons and glati-
ramer showed similar efficacy for relapse measures at 2 years.
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OBJECTIVES: To assess the rate and clinical outcomes of using antiepileptic drugs
(AEDs) at doses above the recommended range (DARR) in pediatric outpatients
with structural-metabolic epilepsy. METHODS: Patients were followed-up retro-
spectively for one year since the first visit. Inclusion criteria were age 2 years; a
diagnosis of structural-metabolic epilepsy; AEDs treatment; and three or more
visits during the first year from the referral time. Exclusion criteria were epilepsy
surgery within the first year from the referral time; and patients not satisfied in-
clusion criteria. During the period from January to June 2010, the required data
were extracted from medical records. Assessment of AEDs doses was based on the
recommended drug doses that were mentioned in “Pediatric Protocols for Malay-
sian Hospitals”. RESULTS: Of 120 followed-up patients, only 13 (10.83%) of them
exposed to AEDs at DARR. In term of visits, 32 (5.68%) visits out of 563 demonstrated
DARR. There was no association between the uses of AEDs at DARR with age,
gender, race, child development, and seizure type. However, the uses of AEDs at
DARR were significantly higher in polytherapy than monotherapy visits (Chi-
square, p0.001). Visits included DARR led to higher seizure frequency than visits
without DARR (Mann-Whitney, P0.001). Ultimately, only patients who weren’t
exposed to AEDs at DARR showed a significant improvement in their seizure con-
trol at the last follow-up visit compared with the baseline (Wilcoxon, P0.001).
CONCLUSIONS: The low frequency of DARR indicates the knowledgeability and
awareness of the in charged pediatric neurologist about consequences of exceed-
ing average effective doses. In term of better seizure control, uses of AEDs at DARR
shows no benefit over using these agents at recommended doses.
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OBJECTIVES: Patients with RRMS can benefit from disease modifying treatments
(DMT) through delayed disease progression and reductions in relapse frequency.
For patients who continue to experience disease activity despite DMT, therapeutic
options have been limited. Understanding the relative prognosis of these sub-
optimally treated (SOT) patients is of considerable interest given the availability of
new treatment options. The aim of our study was to evaluate disease progression of
SOT and non-SOT patients enrolled to the placebo arm of the FREEDOMS® trial.
METHODS: SOT patients were identified as patients who experienced either an
unchanged relapse rate, or at least one relapse with additional disease activity
observed on MRI, despite treatment with a DMT in the prior year. For each patient
group (SOT and non-SOT), Markov state transition matrices were derived. Each
matrix evaluated the annual probability of patients transitioning between stages of
the Expanded Disability Status Scale (EDSS). Comparisons between patient groups
included time to disability greater or equal to () EDSS 4 and EDSS 6, time from
EDSS 4 to disability EDSS 6 and mean EDSS score over time. RESULTS: Median
time to EDSS 4 and EDSS 6 was 5.5 [4.5, 7.5] and 9.0 [7.0, 12.0] years in SOT
patients, compared with 10 [8.5, 12.0] and 18.5 [16.0, 22.5] years in non-SOT pa-
tients. Median time from EDSS 4 to disability greater than EDSS 6 was 3.4 [1.8, 5.4]
years in SOT compared to 5.3 [3.5, 8.0] years in non-SOT patients. Mean EDSS scores
at 2, 5 and 10 years post-onset were estimated at 1.05, 2.55 and 3.21 for SOT and
0.95, 2.13 and 3.07 for non-SOT, respectively.CONCLUSIONS:The analysis suggests
that RRMS patients who experience relapse and MRI activity despite previous treat-
ment with a DMT face faster progression to severe disability states. The analysis
highlights the importance of effective treatment options for these patients.
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OBJECTIVES:Vertigo is a crippling and stressful symptom. It involves the illusion of
movement that manifests itself with an impression of spinning. It is often accom-
panied by neurovegetative signs, but the patient remains conscious during the
attack. Vertigo, often recurrent and sometimes persistent, can strongly alter the
quality of life of patients, to the point of preventing the performance of the majority
of daily activities. It increases the risk of falling and depression or anxiety. Describe
the initial care of patients with vertigo by general practitioners in France.
METHODS: A total of 1400 general practitioners drawn by lot from the general
practitioners practicing in France were contacted, then questioned. RESULTS: The
prevalence of consultations for vertigo and, this being any type of vertigo, is 5.57%,
with one in three is being recurrent vertigo, with an incidence of 2.49%. 45% of the
vertigo cases were not associated with an underlying known pathology (for exam-
ple, a middle ear infection or brain tumour), 40 % of the benign paroxysmal posi-
tional vertigos, 9% Ménière’s disease, 6% a vestibular neuronitis or neuritis 69% of
cases of recurrent vertigo not associated with an underlying pathology are treated
by oral an anti-vertigo drugs, 4% are intravenous, 27% benefit from 2 galenic. Fifty-
seven percent of the general practitioners directly treat their patients’ vertigo, the
others refer them to a specialist. CONCLUSIONS: The epidemiology of recurrent
vertigo (upon the first appearance) has not been studied. It is necessary to point out
that vertigo is, for the most part, recurrent. The interest in this work responds to
this problem situation.
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OBJECTIVES: We used the World Health Organisation database (Vigibase) to eval-
uate the contribution of a global spontaneous adverse event (AE) database for an
analysis of benefit-risk for Glatiramer acetate (GA) in multiple sclerosis.METHODS:
Vigibase is a passive surveillance system that in 2011 contained over 6 million
reports of spontaneous AEs suspected of being linked to health care products from
regulatory authorities in nearly 90 countries. GA, interferon beta-1a, interferon
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